Abstract
Background: Long non-coding RNAs (lncRNA) have been identified as novel molecular regulators in cancers. LncRNA ADAMTS9-AS2 can mediate the occurrence and development of cancer through various ways, such as regulating miRNAs, activating the classical signaling pathways in cancer, and so on, which have been studied by many scholars. In this review, we summarize the molecular mechanisms of ADAMTS9-AS2 in different human cancers.
Methods: Through a systematic search of PubMed, lncRNA ADAMTS9-AS2 mediated molecular mechanisms in cancer are summarized inductively.
Results: ADAMTS9-AS2 aberrantly expression in different cancers is closely related to cancer proliferation, invasion, migration, and inhibition of apoptosis. The involvement of ADAMTS9-AS2 in DNA methylation, mediating PI3K / Akt / mTOR signaling pathways, and regulating miRNAs and proteins, shows its significant potential as a therapeutic cancer target.
Conclusion: LncRNA ADAMTS9-AS2 can become a promising biomolecular marker and a therapeutic target for human cancer.
Keywords: Long non-coding RNA, ADAMTS9-AS2, malignant tumors, therapeutic targets, DNA methylation, mediating PI3K.
Current Pharmaceutical Design
Title:ADAMTS9-AS2: A Functional Long Non-coding RNA in Tumorigenesis
Volume: 27 Issue: 23
Author(s): Wen Xu, Bei Wang , Yuxuan Cai, Jinlan Chen, Xing Lv , Chong Guo and Chengfu Yuan*
Affiliation:
- College of Medical Science, China Three Gorges University, Yichang 443002,China
Keywords: Long non-coding RNA, ADAMTS9-AS2, malignant tumors, therapeutic targets, DNA methylation, mediating PI3K.
Abstract:
Background: Long non-coding RNAs (lncRNA) have been identified as novel molecular regulators in cancers. LncRNA ADAMTS9-AS2 can mediate the occurrence and development of cancer through various ways, such as regulating miRNAs, activating the classical signaling pathways in cancer, and so on, which have been studied by many scholars. In this review, we summarize the molecular mechanisms of ADAMTS9-AS2 in different human cancers.
Methods: Through a systematic search of PubMed, lncRNA ADAMTS9-AS2 mediated molecular mechanisms in cancer are summarized inductively.
Results: ADAMTS9-AS2 aberrantly expression in different cancers is closely related to cancer proliferation, invasion, migration, and inhibition of apoptosis. The involvement of ADAMTS9-AS2 in DNA methylation, mediating PI3K / Akt / mTOR signaling pathways, and regulating miRNAs and proteins, shows its significant potential as a therapeutic cancer target.
Conclusion: LncRNA ADAMTS9-AS2 can become a promising biomolecular marker and a therapeutic target for human cancer.
Export Options
About this article
Cite this article as:
Xu Wen , Wang Bei , Cai Yuxuan , Chen Jinlan , Lv Xing , Guo Chong and Yuan Chengfu *, ADAMTS9-AS2: A Functional Long Non-coding RNA in Tumorigenesis, Current Pharmaceutical Design 2021; 27 (23) . https://dx.doi.org/10.2174/1381612827666210325105106
DOI https://dx.doi.org/10.2174/1381612827666210325105106 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Evolution of the Strategies for Screening and Identifying Human Tumor Antigens
Current Protein & Peptide Science Phenolic Compounds: the Role of Redox Regulation in Neurodegenerative Disease and Cancer
Mini-Reviews in Medicinal Chemistry Targeting p53-MDM2 Interaction Using Small Molecule Inhibitors and the Challenges Needed to be Addressed
Current Drug Targets Progress in Nutritional and Health Profile of Milk and Dairy Products: A Novel Drug Target
Endocrine, Metabolic & Immune Disorders - Drug Targets A Review on Synthetic and Natural Steroid Dimers: 1997-2006
Current Medicinal Chemistry Non-viral Delivery Systems for the Application in p53 Cancer Gene Therapy
Current Medicinal Chemistry A Review of Medicinal Plant Patents
Recent Patents on Biomedical Engineering (Discontinued) Recent Progress of Small Molecular VEGFR Inhibitors as Anticancer Agents
Mini-Reviews in Medicinal Chemistry Amyloidosis and Auto-Inflammatory Syndromes
Current Drug Targets - Inflammation & Allergy Regulatable Gene Expression Systems for Gene Therapy
Current Gene Therapy Apoptosis-related BCL2-family Members: Key Players in Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Dynamic Contrast-Enhanced MRI in Oncology Drug Development
Current Clinical Pharmacology Mechanism of Cancer Drug Resistance and the Involvement of Noncoding RNAs
Current Medicinal Chemistry Current Management of Neonatal Neuroblastoma
Current Pediatric Reviews Therapeutic Potential of Targeting PAK Signaling
Anti-Cancer Agents in Medicinal Chemistry Curcumin and its Formulations: Potential Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Clinical Management of Diabetes Mellitus in the Older Adult Patient
Current Diabetes Reviews An Illustrative Review of Solid Pancreatic Masses: Differential Diagnostic Features of CT and MRI Findings
Current Medical Imaging Insulin-Like Growth Factor 2 - The Oncogene and its Accomplices
Current Pharmaceutical Design Potential Anti-cancer Drugs Commonly Used for Other Indications
Current Cancer Drug Targets